Forecasted · Grant
Alzheimer's Clinical Trials Consortium (ACTC) Clinical Trials
National Institutes of Health, Department of Health and Human Services
Key facts
Copied from the official Grants.gov record. Last verified October 29, 2026.
- Program name
- Alzheimer's Clinical Trials Consortium (ACTC) Clinical Trials
- Issuing agency
- National Institutes of Health (Department of Health and Human Services)
- Opportunity number
- FOR-RFA-AG-26-019
- Funding type
- Grant
- Funding purpose
- Health
- Status
- Forecasted
- Application deadline
- Forecasted · estimated close October 5, 2025 (agency estimate)
- Agency estimates
- Estimated posting: August 1, 2025. Estimated award date: July 1, 2026. Estimates can change.
- Published award range
- Not published by the agency
- Cost sharing or match required
- No
- Eligible applicants (official categories)
- State governments
- County governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Relevant to
- Businesses and NonprofitsHow we determined this: Grants.gov eligibility includes small businesses or for-profit organizations. Grants.gov eligibility includes nonprofit organizations.
- Geographic restrictions
- None stated in structured data (federal opportunities are often nationwide). Check the eligibility details and full announcement for any limits.
- Assistance Listing (CFDA)
- 93.866
- Official source
- View on Grants.gov ↗
- Application URL
- www.grants.gov/search-results-detail/359857 ↗Apply through Grants.gov (Workspace) using the application package on the official listing, unless the full announcement names a different submission system.
- Source identifier
- Grants.gov opportunity ID 359857 · Funding opportunity number FOR-RFA-AG-26-019
- Posted
- June 27, 2025 · Source last updated June 27, 2025
- Last verified
- October 29, 2026 (against Grants.gov)
- Data completeness
- 83% of key fields published by the sourceNot published: published funding range, eligibility criteria text.
- Record confidence
- mediumforecast — dates and amounts are agency estimates.
Description (from the official listing)
The National Institute on Aging (NIA) intends to publish a Notice of Funding Opportunity (NOFO) to invite applications to develop and implement multi-site Phase Ib to III clinical trials of promising pharmacological and non-pharmacological interventions that may prevent, delay, or treat the symptoms of Alzheimer's disease (AD) and AD-related dementias (ADRD) using the Alzheimer's disease Clinical Trials Consortium (ACTC) trial coordination and management infrastructure. Working with the ACTC is a collaborative venture between the applicant, NIA, and the ACTC network. NIA and the ACTC leadership will provide guidance to potential applicants. The work of this NOFO will enable the testing of interventions that target deleterious cognitive and neuropsychiatric changes associated with age-related cognitive decline and AD/ADRD across the spectrum from pre-symptomatic to more severe stages of disease. Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. This NOFO intends to utilize the R01 activity code. Investigators with expertise and insights into this area of aging research are encouraged to begin to consider applying for this NOFO.
Agency contact
Laurie Ryan, Ph.D. National Institute on Aging (NIA)
ryanl@mail.nih.gov